- Ph.D., Chemistry, University of Notre Dame, 2025
- B.S., Chemistry, Simmons University, 2016
- Biochemistry and Integrated Biomedical Sciences Annual Retreat Oral Presentation Award, University of Notre Dame, 2025
- Harper Cancer Research Center Oral Presentation Award, University of Notre Dame, 2025
- Biochemistry and Integrated Biomedical Sciences Annual Retreat Poster Presentation Award: University of Notre Dame, 2024
- Leonard J. Soltzberg Departmental Service Award, Simmons University, 2016
- Francis F. Zion Endowed Scholarship, Simmons University, 2016
- Outstanding Chapter Award, Americal Chemical Society, 2015
- Green Chemistry Student Chapter Award, Americal Chemical Society, 2015
- American Chemical Society (ACS)
- Sigma Xi – Scientific Research Honors Society
- Harper Cancer Research Center, University of Notre Dame
- Warren Drug Discovery Center, University of Notre Dame
Caitlin L. Horgan, Ph.D., is a Scientist in Exponent's Biomedical Engineering & Sciences practice, focusing on biological characterization, analytical method development, biomaterials, drug-delivery systems, microbiology, and in vitro diagnostic technologies. She helps clients evaluate product performance, biological interactions, contamination risks, analytical data, and development challenges involving pharmaceuticals, biologics, medical devices, diagnostics, biomaterials, and advanced therapeutic platforms.
Dr. Horgan's expertise is founded on interdisciplinary training in microbiology, immunology, analytical chemistry, biomaterials, and pharmaceutical development. She applies experimental and analytical approaches to characterize complex products and biological systems, investigate sources of variability or performance limitations, and evaluate interactions among microorganisms, proteins, biomaterials, therapeutics, and medical products. Her experience spans analytical method development and validation, assay development, formulation optimization, technology transfer, contamination testing, stability assessment, and translational product development across research, clinical, and regulated environments.
Prior to joining Exponent, Dr. Horgan conducted research at AstraZeneca, the University of Notre Dame, the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School, and Simmons University. Her work included development of analytical methods for pathogen-associated molecular patterns, lipid nanoparticle and drug-delivery technologies, allergy diagnostics and immunoassays, clinical-trial support, and pre-IND formulation development.
Biological Characterization & Product Development
Dr. Horgan assists clients in understanding how biological materials, biomaterials, therapeutics, and medical products interact with complex biological systems. She evaluates biological performance, identifies factors influencing product behavior, and assesses relationships among formulation, structure, function, and clinical application. Her experience includes characterization of immunological responses, biological compatibility, protein-pathogen interactions, and stability of products ranging from small molecules to novel therapeutic platforms. She helps clients interpret scientific evidence supporting product development, performance assessment, regulatory decision-making, and translational research.
Microbiology & Molecular Biology
Dr. Horgan provides consulting support involving microbiological systems, microbial materials, and biologically derived products. Her experience includes bacterial, fungal, and mammalian cell culture; pathogen-associated molecular pattern characterization; endotoxin assessment; nucleic acid and protein purification; molecular biology techniques; and biological characterization of microorganisms and microbial products. She integrates microbiological, molecular biological, and analytical approaches to evaluate microbial testing data, contamination-related concerns, biological materials, and microbiologically influenced product performance.
In Vitro Diagnostics & Assay Development
Dr. Horgan supports clients developing and evaluating in vitro diagnostic technologies, immunoassays, biomarker assays, and biologically based analytical methods. Her experience includes assay design, optimization, validation, and performance assessment, including technologies for allergy detection, pathogen characterization, and biomarker quantification. Her expertise includes ELISA-based methods, immunoassays, flow cytometry, cellular studies, binding assays, and biomarker quantification approaches.
Biomaterials, Nanoparticles & Drug-Delivery Systems
Dr. Horgan assists clients in evaluating biomaterials, lipid nanoparticle systems, targeted drug-delivery platforms, and advanced therapeutic technologies. Her experience includes formulation development, nanoparticle characterization, biomaterial functionalization, targeted delivery strategies, stability assessment, payload encapsulation, and biological performance evaluation. She helps clients understand how formulation variables, particle characteristics, material properties, and biological interactions influence product performance, manufacturability, and translational potential.
Analytical Development & Characterization
Dr. Horgan provides consulting support involving analytical method development, product characterization, and interpretation of complex analytical datasets. Her experience includes chromatographic separations, protein characterization, materials characterization, nanoparticle analysis, and orthogonal analytical testing strategies. She assists clients in evaluating analytical methods, interpreting laboratory findings, investigating variability, comparing analytical approaches, and establishing scientifically supported conclusions regarding product identity, quality, stability, and performance.
Study Design, Data Analysis & Translational Development
Dr. Horgan assists clients in designing studies, evaluating experimental data, and supporting product-development programs spanning early research through translational development. Her experience includes Design of Experiments (DOE), statistical analysis, root-cause investigation, analytical method validation, technology transfer, clinical-trial support, cGLP/cGMP studies, pre-IND development activities, and in vivo study design. She helps clients optimize development strategies and interpret findings for product development and regulatory decision-making.